Description
A homolog of vitamin K2; formed primarily via conversion of vitamin K1 in vivo; halts the cell cycle at the G1 phase in HepG2, Hep3B, and Huh7 hepatocellular carcinoma cells in a concentration-dependent manner; inhibits IκB, IκBα phosphorylation, and the transcriptional activity of NF-κB
Formal name: 2-methyl-3-[(2E,6E,10E)-3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraen-1-yl]-1,4-naphthalenedione
Synonyms: MK-4|Vitamin K2(20)
Molecular weight: 444.7
CAS: 863-61-6
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Kinase Inhibitors|IKKs||Product Type|Biochemicals|Natural Products|Vitamins||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Product Type|Biochemicals|Small Molecule Inhibitors|TNF-α/NF-κB Signaling||Research Area|Cancer|Cell Cycle|G1||Research Area|Cancer|Cell Signaling|NF-κB Signaling||Research Area|Cancer|Transcription Factors|NF-κB||Research Area|Endocrinology & Metabolism|Bone Growth & Remodeling||Research Area|Endocrinology & Metabolism|Cofactors & Vitamins
